Mestranol/hydroxyprogesterone acetate

Mestranol /
hydroxyprogesterone acetate
	Mestranol (top) and; hydroxyprogesterone acetate (bottom)
Combination of
Mestranol	Estrogen
Hydroxyprogesterone acetate	Progestogen
Clinical data
Trade names	Hormolidin
Other names	ME/OHPA; EEME/OHPA
Routes of; administration	By mouth
Drug class	Estrogen; Progestogen

Mestranol/hydroxyprogesterone acetate (ME/OHPA), sold under the brand name Hormolidin, is a combination medication of mestranol (ME), an estrogen, and hydroxyprogesterone acetate (OHPA), a progestin, which was reportedly used as a sequential combined birth control pill for women in the early 1970s.^[1] It was formulated as oral tablets and contained 16 tablets of 80 μg ME, 5 tablets of 80 μg ME and 100 mg OHPA, and 7 placebo tablets (28 tablets in total).^[1] The medication was manufactured by the pharmaceutical company Gador in Argentina.^[1]

References

^ ^a ^b ^c Rudel HW, Kinel FA (September 1972). "Oral Contraceptives. Human Fertility Studies and Side Effects". In Tausk M (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 385–469. ISBN 978-0080168128. OCLC 278011135.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.